سعر كارينوبا 250/25 مجم 20 قرص 2024

Egyptian orally disintegrating tablet combining levodopa 250 mg and carbidopa 25 mg, marketed by Elixir Pharma for Parkinson's disease.

• Parkinson's diseasePopulation: Patients with Parkinson's diseaseElixir Pharma (official website)
• Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism following carbon monoxide or manganese intoxicationPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common: dyskinesias (choreiform, dystonic and other involuntary movements) and nausea. Others include orthostatic hypotension, confusion, hallucinations, somnolence, dark urine/saliva/sweat, and impulse-control symptoms.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Concomitant use of nonselective MAO inhibitors (stop them at least 2 weeks before starting).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to any component, and narrow-angle glaucoma.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Levodopa alone must be stopped at least 12 hours before starting carbidopa/levodopa. Dyskinesias may occur at lower doses than with levodopa alone; watch for depression with suicidal tendencies; use cautiously in severe cardiovascular, pulmonary, renal, hepatic or endocrine disease, bronchial asthma, and history of peptic ulcer.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• May reduce vitamin B6 levels; seizures linked to vitamin B6 deficiency have been reported. Check vitamin B6 before and during treatment and supplement if low.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Nonselective MAO inhibitorsContraindicated; discontinue at least two weeks before starting therapy. Selective MAO-B inhibitors (e.g. selegiline) may be used at recommended doses.DailyMed (U.S. National Library of Medicine)

• No adequate and well-controlled studies in pregnant women; carbidopa/levodopa caused visceral and skeletal malformations in rabbits. Levodopa crosses the human placenta. Weigh benefits against possible hazards to mother and child.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Levodopa has been detected in human milk; use caution in nursing women.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Levodopa: Crosses the blood-brain barrier and is converted to dopamine in the brain.
• Carbidopa: Inhibits peripheral decarboxylation of levodopa so that more levodopa reaches the brain.